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Introduction: Pulmonary alveolar proteinosis is a rare pulmonary disease characterized by excessive alveolar
accumulation of surfactant due to defective alveolar clearance by macrophages. There are only a few published
case reports of pulmonary alveolar proteinosis occurring in association with solid cancers. To the best of our
knowledge, there are no previously reported cases of pulmonary alveolar proteinosis associated with breast cancer.
Case presentation: A 48-year-old Asian woman, a nonsmoker, presented to our institution with a right breast mass.
Biopsy examination of the lesion revealed scirrhous carcinoma. A chest computed tomography scan for metastases
showed abnormal shadows in both upper lung fields. As a result of flexible fiberscopic bronchoscopy, this patient
was diagnosed as having pulmonary alveolar proteinosis. This case was categorized as autoimmune pulmonary
alveolar proteinosis due to the positive anti-granulocyte-macrophage colony-stimulating factor antibody. Pulmonary
alveolar proteinosis decreased gradually after mastectomy.
Conclusions: The present case involved the coincident occurrence of autoimmune pulmonary alveolar proteinosis
with breast cancer; breast cancer may be a factor during pulmonary alveolar proteinosis development.
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Pulmonary alveolar proteinosis (PAP), first described in
1958 [1], is an unusual disease characterized by the ac-
cumulation of large amounts of surfactant lipids and
proteins in the alveolar spaces. This material may be re-
sponsible for pulmonary symptoms and impairment of
gas exchange leading to respiratory failure. It has been
observed both as an isolated process and in conjunction
with a variety of inflammatory and neoplastic diseases of
the hematopoietic and immune systems. There are only
a few published case reports of PAP occurring in associ-
ation with solid cancers [2-8].
Case presentation
A 48-year-old, Asian woman, a nonsmoker, presented to
our institution with a right breast mass. A physical
examination revealed a hard mass in her right breast.
There was no tenderness and no skin redness. The mass
had a clear border and good mobility, and there was* Correspondence: toyosawai@yahoo.co.jp
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unless otherwise stated.right axillary lymph node swelling. Ultrasonography dis-
played an inhomogeneous hypoechoic nodule measuring
20mm×17mm (Figure 1). Biopsy examination of the le-
sion revealed scirrhous carcinoma. A chest computed
tomography (CT) scan for metastases showed abnormal
shadows in both upper lung fields. The patient was then
referred to our department for definitive workup and
treatment. She had no history of cough, sputum, or dys-
pnea. Our patient had no history of tobacco smoking
and no exposure to any dusts associated with a high risk
of lung damage. Her past history and family history were
unremarkable. A chest X-ray showed slight peripheral
infiltration shadows in both upper and middle lung fields
(Figure 2). A chest CT scan showed patchy peripheral
ground-glass opacities and thickened interlobular septa
in both upper lung fields (Figure 3A). A peripheral blood
cell count and serum and biochemical tests were normal.
Autoantibody and vasculitis screening was negative. Test-
ing for human immunodeficiency virus infection was
negative. Serum carcinoembryonic antigen (CEA) and
carbohydrate antigen 15–3 (CA15-3) were in the normal
ranges (1.1ng/mL and 12.5U/mL, respectively), but
granulocyte-macrophage colony-stimulating factor (GM-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasonography shows an inhomogeneous, hypoechoic
nodule measuring 20mm×17mm.
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function testing revealed normal lung volumes and diffus-
ing capacity. Flexible fiberscopic bronchoscopy was then
performed. The retrieved bronchoalveolar lavage fluid
(BALF) was transparent; it did not have a milky appear-
ance. However, BALF cytology showed alveolar macro-
phages with granular materials that stained positively with
periodic acid-Schiff (PAS). Histological findings of a trans-
bronchial lung biopsy specimen showed the alveolarFigure 2 The chest X-ray shows slight peripheral infiltration
shadows in both upper and middle lung fields.spaces to be filled with PAS-positive granular materials
(Figure 4). As a result, this patient was diagnosed as hav-
ing PAP.
Because she was asymptomatic and her oxygenation
was good, a right modified radical mastectomy was per-
formed. One month after surgery, the chest CT scan was
repeated. It showed that the areas of ground-glass opaci-
ties and thickened interlobular septa representing PAP
had decreased (Figure 3B). This patient required no further
treatment after surgery. On follow-up, she had remained
asymptomatic with respect to pulmonary disease, with no
recurrence.
Discussion
PAP is an unusual disease characterized by the accumu-
lation of surfactant composed of proteins and lipids in
pulmonary alveolar macrophages and alveoli due to de-
fective alveolar clearance by macrophages. It has been
observed both as an isolated process and in conjunction
with a variety of inflammatory conditions such as infec-
tions, pneumoconiosis, and hematologic malignancies of
the immune or hematopoietic systems, including leukemia,
and lymphoma. In many of these conditions, defective
or altered macrophage function has been demonstrated.
Sakagami et al. reported that GM-CSF autoantibodies
reproduce the pathologic manifestations of PAP in healthy
macaques [9].
PAP is divided into the following three distinct clinical
forms based on its etiology: autoimmune, secondary, and
congenital [10]. Autoimmune PAP represents approxi-
mately 90 percent of PAP cases and is caused by neutral-
izing antibodies against GM-CSF. These populations are
mostly normal hosts without underlying disease. Sec-
ondary PAP has been described in association with a
variety of inflammatory and neoplastic diseases of the
hematopoietic and immune systems that impair alveolar
macrophage function, resulting in surfactant accumula-
tion [11]. Congenital PAP is seen especially in children,
and the radiological and clinical presentation depends
on the gene mutations in encoding surfactant protein B
or C or the ABCA3 transporter by the absence of GM-
CSF receptor [12].
The association between secondary PAP and hematological
disorders, mostly chronic myeloid leukemia, myelodys-
plastic syndrome, and lymphoma, is well established [11].
However, there have been only a few published case re-
ports of PAP occurring in association with solid cancers,
including five lung cancers, one metastatic pulmonary
melanoma, one mesothelioma and one glioblastoma [2-8].
Of the eight cases, detection of GM-CSF autoantibodies
was performed in only two lung cancer cases (Table 1);
one was a case of autoimmune PAP with subsequent de-
velopment of lung cancer [7], and the other was secondary
PAP associated with lung cancer [8]. Liu et al. [8]
Figure 3 Serial chest computed tomography shows gradual resolution. (A) The chest computed tomography scan shows patchy peripheral
ground-glass opacities and thickened interlobular septa in both upper lung fields (November 2013). (B) The chest computed tomography scan
shows that the areas of ground-glass opacities and thickened interlobular septa representing pulmonary alveolar proteinosis have decreased
(January 2014).
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hibitors secreted from the lung cancer cells causing a local
inhibitory effect on macrophages probably induced PAP.
Furthermore, Athanassiadou et al. [13] reported that pa-
tients with primary lung cancer have a high number of
functionally incompetent macrophages. In autoimmune
PAP patients, Inoue et al. reported that four of 212 cases
(1.9 percent) were associated with cancers, including
lung cancer, colon cancer, prostatic cancer, and thyroid
cancer [10]. Since the average age at diagnosis of PAP is
40 to 50 years, PAP with cancer may be rare. To the best
of our knowledge, PAP with breast cancer has not been
previously described. The present case of PAP co-existed
with breast cancer, but this case was categorized as auto-
immune PAP due to the positive anti-GM-CSF antibody.
However, GM-CSF autoantibodies are also present in
healthy persons and in immune globulin prepared from
plasma obtained from healthy persons [9]. Certainly, high
levels of GM-CSF autoantibodies are specifically associ-
ated with autoimmune PAP. Kitamura et al. reported
that the mean level of the autoantibodies in the sera
from 24 idiopathic (autoimmune) PAP patients was 180
±22μg/mL, but the range was 35 to 430μg/mL [14]. TheFigure 4 Histological findings of transbronchial lung biopsy specimens sh
(A; hematoxylin and eosin, ×200) and abundant intra-alveolar materialanti-GM-CSF antixbody of this patient was increased to
29.57μg/mL, but still less than 35μg/mL. Moreover, PAP
decreased one month after breast cancer resection. A pre-
vious report found that significant spontaneous resolution
of PAP occurred in 7.9 percent (24 of 303 cases) of pa-
tients [15], but the median time from diagnosis to reso-
lution was 20 months. Thus, breast cancer may have been
a factor during PAP development in this patient. Morgan
et al. reported that breast cancer cells induced enhance-
ment of osteoblast-stromal cells to increase prostaglandin
E2 (PGE2) production, and the release of PGE2 downreg-
ulated GM-CSF production in vitro [16]. Liu et al. re-
ported that overexpression of cytokeratin-associated
protein (CAPC) in MDA-231 breast cancer cells downreg-
ulated nuclear factor κB (NF-κB) activity and its target
genes, including GM-CSF, in vitro [17]. These findings
suggest that the process of breast cancer causes a local in-
hibitory effect on macrophages.
Conclusions
In conclusion, the first case of PAP co-existing with
breast cancer was described. The present case involved
the coincident occurrence of autoimmune PAP withow the alveolar spaces to be filled with eosinophilic granular material
that stains with periodic acid-Schiff (B; periodic acid-Schiff, ×200).
Table 1 Clinical features of nine patients with solid organ cancer and pulmonary alveolar proteinosis reported in the
literature
Case/Ref Sex/age (y) Presentation Clinical form GM-CSF Ab Cancer Timing of cancer and PAP
1/2) M/24 Weight loss Unknown N.A. Melanoma Co-incident
2/3) M/64 Lt. hemiplegia Unknown N.A. Glioblastoma Cancer first
3/4) M/67 Cough, Sputum Unknown N.A. Lung cancer (SCC) Co-incident
4/5) M/59 Cough, Dyspnea Unknown N.A. Lung cancer (SCC) Co-incident
5/6) M/45 Chest pain Unknown N.A. Mesothelioma PAP first
6/7) F/54 Dyspnea Autoimmune Positive Lung cancer (Adeno) PAP first
7/7) F/59 Dyspnea Unknown N.A. Lung cancer (Adeno) Co-incident
8/8) M/57 Cough, Sputum Secondary Negative Lung cancer (SCC) PAP first
9/our case F/48 Asymptomatic Autoimmune Positive Breast cancer Co-incident
GM-CSF Ab, granulocyte-macrophage colony-stimulating factor antibody; PAP, pulmonary alveolar proteinosis; N.A., not available; SCC, squamous cell carcinoma;
Adeno, adenocarcinoma.
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be a factor during PAP development.
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